Fullerton Fund Management Co Ltd. Buys 1,374 Shares of Stryker Co. (NYSE:SYK)

Fullerton Fund Management Co Ltd. increased its holdings in Stryker Co. (NYSE:SYK) by 34.9% during the 4th quarter, according to its most recent Form 13F filing with the SEC. The fund owned 5,309 shares of the medical technology company’s stock after purchasing an additional 1,374 shares during the period. Fullerton Fund Management Co Ltd.’s holdings in Stryker were worth $1,912,000 at the end of the most recent quarter.

A number of other institutional investors have also recently made changes to their positions in the business. Kohmann Bosshard Financial Services LLC bought a new stake in shares of Stryker in the 4th quarter valued at approximately $25,000. Rakuten Securities Inc. boosted its position in shares of Stryker by 618.2% during the fourth quarter. Rakuten Securities Inc. now owns 79 shares of the medical technology company’s stock valued at $28,000 after buying an additional 68 shares during the period. Centricity Wealth Management LLC bought a new position in shares of Stryker during the fourth quarter valued at approximately $30,000. BankPlus Trust Department bought a new stake in shares of Stryker during the 4th quarter worth approximately $33,000. Finally, VSM Wealth Advisory LLC purchased a new position in Stryker during the 4th quarter valued at $36,000. Institutional investors own 77.09% of the company’s stock.

Stryker Trading Down 0.4 %

Stryker stock opened at $380.87 on Friday. Stryker Co. has a 52 week low of $314.93 and a 52 week high of $406.19. The stock has a 50-day moving average price of $365.47 and a 200 day moving average price of $374.30. The company has a quick ratio of 1.32, a current ratio of 1.95 and a debt-to-equity ratio of 0.59. The company has a market capitalization of $145.37 billion, a price-to-earnings ratio of 49.08, a price-to-earnings-growth ratio of 2.93 and a beta of 0.93.

Stryker (NYSE:SYK) last released its quarterly earnings data on Thursday, May 1st. The medical technology company reported $2.84 earnings per share for the quarter, topping analysts’ consensus estimates of $2.73 by $0.11. Stryker had a net margin of 13.25% and a return on equity of 23.58%. The firm had revenue of $5.87 billion for the quarter, compared to analyst estimates of $5.68 billion. During the same quarter in the prior year, the business earned $2.50 earnings per share. The business’s quarterly revenue was up 11.9% compared to the same quarter last year. Sell-side analysts anticipate that Stryker Co. will post 13.47 EPS for the current year.

Stryker Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Thursday, July 31st. Shareholders of record on Monday, June 30th will be issued a $0.84 dividend. This represents a $3.36 dividend on an annualized basis and a yield of 0.88%. The ex-dividend date of this dividend is Monday, June 30th. Stryker’s payout ratio is presently 45.41%.

Insider Transactions at Stryker

In other Stryker news, Director Allan C. Golston sold 2,458 shares of the company’s stock in a transaction dated Tuesday, February 18th. The shares were sold at an average price of $383.07, for a total value of $941,586.06. Following the completion of the transaction, the director now owns 14,895 shares in the company, valued at approximately $5,705,827.65. This represents a 14.16 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Also, Director Ronda E. Stryker sold 200,000 shares of the business’s stock in a transaction that occurred on Tuesday, May 6th. The shares were sold at an average price of $376.96, for a total value of $75,392,000.00. Following the completion of the sale, the director now owns 3,417,326 shares of the company’s stock, valued at $1,288,195,208.96. This trade represents a 5.53 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Corporate insiders own 5.90% of the company’s stock.

Analyst Upgrades and Downgrades

SYK has been the topic of a number of research analyst reports. The Goldman Sachs Group set a $422.00 price target on shares of Stryker in a report on Tuesday, March 4th. Barclays raised their price target on Stryker from $418.00 to $443.00 and gave the company an “overweight” rating in a research note on Monday, February 10th. Evercore ISI cut their target price on shares of Stryker from $400.00 to $390.00 and set an “outperform” rating on the stock in a research report on Friday, May 2nd. Royal Bank of Canada boosted their price objective on shares of Stryker from $425.00 to $435.00 and gave the stock an “outperform” rating in a research note on Wednesday, January 29th. Finally, Truist Financial lifted their price target on Stryker from $390.00 to $400.00 and gave the company a “hold” rating in a report on Monday, May 5th. Five analysts have rated the stock with a hold rating and fifteen have given a buy rating to the stock. According to MarketBeat, Stryker has a consensus rating of “Moderate Buy” and a consensus target price of $427.05.

About Stryker

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.